IKT
Closed
Inhibikase Therapeutics inc
1.95
0.00 (0.00%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 1.95
Day's Range: 1.82 - 1.97
Send
sign up or login to leave a comment!
When Written:
0.612
Inhibikase Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on developing small molecule drugs to treat infectious diseases, neurological disorders, and cancer. The company was founded in 2008 and is headquartered in Atlanta, Georgia. Inhibikase's lead drug candidate, IkT-148009, is being developed for the treatment of Parkinson's disease and is currently in Phase 1 clinical trials. The company's other drug candidates include IkT-001Pro, which is being developed for the treatment of tuberculosis, and IkT-001Plus, which is being developed for the treatment of COVID-19. Inhibikase's drug development platform is based on its proprietary technology, which enables the discovery and development of small molecule drugs that target protein kinases.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








